Use of Adjuvants in Vaccines to Offer Lucrative Growth Prospects
The growing usage of integrated unit vaccinations is propelling the adjuvant industry forward. The need for different adjuvants is increasing as consumption rises. More development is projected in the next years, which will raise the need for adjuvants. The market is predicted to develop at a modest pace, owing to the rising use of biologics and biosimilars, as well as increased R&D in vaccines throughout the globe. Unmet demand for specialised vaccinations, higher government immunisation recommendations, technical advancements, and greater usage of combination and synthetic vaccines are all factors that contribute to the development of the adjuvants vaccine market.
Growing Vaccination Awareness to Boost Market Growth
Over the past years, national and local bodies have taken efforts to aware public of benefits of vaccine immunization. The media plays an important role in spreading awareness among the general public regarding pros and cons of vaccine immunization. With the growing level of medica coverage in rural parts of developing and under-developed economies, the market for live vaccines is anticipated to witness lucrative opportunities over the forecast period.
What are the Growth Drivers for Vaccine Sales Market?
• Rising Focus and Government Support on Immunization Programs
• Growing Investment in Vaccine Development
• Increasing Company Initiatives to Enhance Vaccine R&D
• High Prevalence of Infectious Diseases
• Technological Advancements in Vaccine Administration
• Rapid Need of Immunization
• Strong Supply Backed Up by Robust R&D to Drive the Market
What are the Challenges for Vaccine Sales Market?
• Inadequate Reimbursement Coverage
• High Cost of Vaccine Development
• Long Timelines of Vaccine Manufacturing Hinder the Growth of the Vaccines Market
• Stringent Government Regulations for Approval
What are the Market Opportunities?
• High Growth Prospects in Emerging Markets
• Focus on Therapeutic Vaccines
• Use of Adjuvants in Vaccines
• Government Support for Future Vaccine R&D
Long Timelines of Vaccine Manufacturing Projected to Hinder Vaccines Market Growth
Vaccine development is seen as an expensive, difficult, and time-consuming process because to the intricacy of manufacturing and accompanying processes, which may take up to 10–15 years. Due to the endless combinations of biological ingredients, microorganisms, equipment employed, ambient conditions, and culture stages, results may vary greatly throughout manufacturing. Furthermore, the reagents and procedures needed to monitor culture parameters add to the process' complexity, prolonging production times.
Furthermore, product approvals from regulatory bodies take longer since the authorities evaluate the product's quality and effectiveness, as well as the manufacturing process. After the producers show enough pre-clinical evidence on the vaccines' safety to confirm the vaccines' action in people, the vaccines start clinical trials. Even after approval, each year, vaccination batches are evaluated for safety and stability to guarantee compliance with regulatory requirements. Furthermore, the longer the deadlines, the greater the production cost, which restricts new manufacturers from entering the market, stifling growth.
Discover how to stay ahead
Our 620+ page report provides 640+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Vaccine Sales Market. See how to exploit the opportunities.
Forecasts to 2032 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), PEST Analysis, Porter’s Five Forces, SWOT Analysis, product profiles and commercial developments.
Discover sales predictions for the world market and sub-markets
Indication
• Pneumococcal
• Rotavirus
• Influenza
• Hepatitis
• COVID-19
• Measles
• Mumps & Varicella
• Typhoid
• Meningococcal
• DPT
• Others
Route of Administration
• Intramuscular
• Subcutaneous
• Oral
Type
• Inactivated
• Live Attenuated
• Toxoid
• Recombinant/Conjugate/Subunit
Distribution Channel
• Hospital & Retail Pharmacies
• Government Suppliers
• Others
Age Group
• Pediatrics
• Adults
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
By Region
• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• GCC
• South Africa
• Rest of Middle East & Africa
Leading companies and the potential for market growth
Overall world revenue for Vaccine Sales Market will surpass $xx billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
Prospects for established firms and those seeking to enter the market– including company profiles for 20 of the major companies involved in the Vaccine Sales market. Some of the companies profiled in this report include Bavarian Nordic, Bharat Biotech, CSL Limited, Daiichi Sankyo Co., Emergent BioSolutions Inc., GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc., J&J, Merck Co., Inc., Mitsubishi Tanabe Pharma Corporation, Moderna, Inc., Novavax, Panacea Biotec Ltd., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Sinopharm, SINOVAC, and Takeda Pharmaceutical Company Limited among other prominent players.
How the Vaccine Sales Market report helps you
In summary, our 620+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Vaccine Sales Market, with forecasts for 11 indications, 3 route of administration, 4 types, 3 distribution channel, and 2 age groups , each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2032 for 5 regional and 20 key national markets– See forecasts for the Vaccine Sales market in North America, Europe, Asia Pacific, and Rest of the World. These regional markets have been further bifurcated by countries including US, Canada, Brazil, Mexico, Germany, France, UK, Italy, Spain, Russia, China, India, Japan, Australia, South Korea, and South-East Asia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 20 of the companies involved in the Vaccine Sales Market. Some of the company’s profiled in this report include Bavarian Nordic, Bharat Biotech, CSL Limited, Daiichi Sankyo Co., Emergent BioSolutions Inc., GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc., J&J, Merck Co., Inc., Mitsubishi Tanabe Pharma Corporation, Moderna, Inc., Novavax, Panacea Biotec Ltd., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Sinopharm, SINOVAC, and Takeda Pharmaceutical Company Limited, among other prominent players.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Vaccine Sales Market and leading companies. You will find data, trends, and predictions.
'
1. Report Overview
1.1 Introduction to Vaccine Sales Market
1.1 Vaccine Technologies
1.1.1 Live-Attenuated Vaccines
1.1.2 Inactivated Vaccines
1.1.3 Toxoid Vaccines
1.1.4 Subunit Vaccines
1.1.5 Virus-Like Particles (VLP) Vaccines
1.1.6 Bacterial Outer Membrane Vesicle (OMV) Vaccines
1.2 Platform-based Vaccines
1.2.1 DNA Vaccines
1.2.2 mRNA Vaccines
1.2.3 Viral Vector Vaccines
1.3 Vaccine Sales Market Definition
1.4 Why You Should Read This Report
1.5 What This Report Delivers
1.6 Key Questions Answered By This Analytical Report Include:
1.7 Who is This Report For?
1.8 Methodology
1.8.1 COVID-19 Impact: Recovery Scenarios
1.8.2 Market Evaluation & Forecasting Methodology
1.9 Frequently Asked Questions (FAQs)
1.10 Associated Reports
1.11 About
2 Executive Summary
2.1 COVID-19 Vaccine Tracker
2.2 Top Recipients of COVID-19 R&D Funding
2.3 North America Leading the Overall Vaccines Market
2.4 Strong Portfolio has Propelled Sanofi & Pfizer to Dominate the Worldwide Vaccines Market
3 Global Vaccine Sales Market Dynamics
3.1 COVID-19 Impact on the Vaccine Sales Market
3.2 Current Trends in the Vaccine Sales Market
3.3 Market Driving Factors
3.3.1 Rising Focus and Government Support on Immunization Programs
3.3.2 Growing Investment in Vaccine Development
3.3.3 Increasing Company Initiatives to Enhance Vaccine R&D
3.3.4 High Prevalence of Infectious Diseases
3.3.5 Technological Advancements in Vaccine Administration
3.3.6 Rapid Need of Immunization
3.3.7 Strong Supply Backed Up by Robust R&D to Drive the Market
3.4 Market Restraining Factors
3.4.1 Inadequate Reimbursement Coverage
3.4.2 High Cost of Vaccine Development
3.4.3 Long Timelines of Vaccine Manufacturing Hinder the Growth of the Vaccines Market
3.4.4 Stringent Government Regulations for Approval
3.4.5 Inadequate Access to Vaccines
3.4.6 Product Recalls
3.5 Opportunities in the Global Market
3.5.1 High Growth Prospects in Emerging Markets
3.5.2 Focus on Therapeutic Vaccines
3.5.3 Use of Adjuvants in Vaccines
3.5.4 Government Support for Future Vaccine R&D
3.6 SWOT Analysis
3.6.1 Strengths
3.6.1.1 Growing Demand from Emerging Economies
3.6.1.2 Prevention is Better Than Cure
3.6.1.3 Growing Vaccination Awareness to Boost Market Growth
3.6.2 Weaknesses
3.6.2.1 Strong Entry Barriers to Challenge Market Growth
3.6.2.2 Capital Intensive Business
3.6.3 Opportunities
3.6.3.1 Technological Advancements
3.6.3.2 Innovations in Vaccine Market
3.6.4 Threats
3.6.4.1 Maximum Market Share Captured by Few Global Vaccine Manufacturers
3.6.4.2 Productivity Gap
3.7 PEST Analysis
4 Global Vaccine Sales Market Analysis
4.1 Global Market Outlook
4.2 Global Market Size Estimation and Forecast
4.2.1 Pre-COVID-19 Market Scenario
4.2.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis
5 Global Vaccine Sales Market Analysis by Region
5.1 North America
5.2 Europe
5.3 Asia Pacific
5.4 Latin America
5.5 MEA
5.6 Regional Market Size Estimation and Forecast
5.6.1 Pre-COVID-19 Market Scenario
5.6.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis
6 Global Vaccine Sales Market Analysis by Indication
6.1 Segment Overview
6.2 Pneumococcal
6.3 Rotavirus
6.4 Influenza
6.5 Hepatitis
6.6 COVID-19
6.7 Measles
6.8 Mumps & Varicella
6.9 Typhoid
6.10 Meningococcal
6.11 DPT
6.12 Global Market Size Estimation and Forecast by Indication
6.12.1 Pre-COVID-19 Market Scenario
6.12.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis
7 Global Vaccine Sales Market Analysis by Route of Administration
7.1 Segment Overview
7.2 Intramuscular
7.3 Subcutaneous
7.4 Oral
7.5 Global Market Size Estimation and Forecast by Route of Administration
7.5.1 Pre-COVID-19 Market Scenario
7.5.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis
8 Global Vaccine Sales Market Analysis by Type
8.1 Segment Overview
8.2 Inactivated
8.3 Live Attenuated
8.4 Toxoid
8.5 Recombinant/Conjugate/Subunit
8.6 Global Market Size Estimation and Forecast by Type
8.6.1 Pre-COVID-19 Market Scenario
8.6.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis
9 Global Vaccine Sales Market Analysis by Distribution Channel
9.1 Segment Overview
9.2 Hospital & Retail Pharmacies
9.3 Government Suppliers
9.4 Global Market Size Estimation and Forecast by Distribution Channel
9.4.1 Pre-COVID-19 Market Scenario
9.4.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis
10 Global Vaccine Sales Market Analysis by Age Group
10.1 Segment Overview
10.2 Pediatrics
10.3 Adults
10.4 Global Market Size Estimation and Forecast by Age Group
10.4.1 Pre-COVID-19 Market Scenario
10.4.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis
11 North America Vaccine Sales Market
11.1 Introduction
11.2 North America Vaccine Sales Market by Country, Forecast 2022-2032
11.3 North America Vaccine Sales Market Forecast by Indication
11.4 North America Vaccine Sales Market Forecast by Route of Administration
11.5 North America Vaccine Sales Market Forecast by Type
11.6 North America Vaccine Sales Market Forecast by Distribution Channel
11.7 North America Vaccine Sales Market Forecast by Age Group
11.8 U.S. Vaccine Sales Market Forecast, 2022-2032
11.8.1 Introduction
11.8.2 U.S. Vaccine Sales Market Revenue, 2022-2032
11.8.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): U.S. Vaccine Sales Market Forecast, 2022-2032
11.9 Canada Vaccine Sales Market Forecast, 2022-2032
11.9.1 Introduction
11.9.2 Canada Vaccine Sales Market Revenue, 2022-2032
11.9.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Canada Vaccine Sales Market Forecast, 2022-2032
12 Europe Vaccine Sales Market
12.1 Introduction
12.2 Europe Vaccine Sales Market by Country, Forecast 2022-2032
12.3 Europe Vaccine Sales Market Forecast by Indication
12.4 Europe Vaccine Sales Market Forecast by Route of Administration
12.5 Europe Vaccine Sales Market Forecast by Type
12.6 Europe Vaccine Sales Market Forecast by Distribution Channel
12.7 Europe Vaccine Sales Market Forecast by Age Group
12.8 Germany Vaccine Sales Market Forecast, 2022-2032
12.8.1 Germany Well Positioned with an Established Healthcare System
12.8.2 Germany Vaccine Sales Industry Analysis
12.8.3 Germany Vaccine Sales Market Revenue, 2022-2032
12.8.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): Germany Vaccine Sales Market Forecast, 2022-2032
12.9 UK Vaccine Sales Market Forecast, 2022-2032
12.9.1 UK Vaccine Sales Industry Analysis
12.9.2 Technological Advancements to Fuel Market Growth
12.9.3 Need to Invest in Vaccines to Offer Lucrative Growth Opportunities
12.9.4 UK Vaccine Sales Market Revenue, 2022-2032
12.9.5 COVID-19 Impact Recovery Scenarios (V, U, W, L): UK Vaccine Sales Market Forecast, 2022-2032
12.10 France Vaccine Sales Market Forecast, 2022-2032
12.10.1 France Vaccine Sales Industry Analysis
12.10.2 France Vaccine Sales Market Revenue, 2022-2032
12.10.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): France Vaccine Sales Market Forecast, 2022-2032
12.11 Italy Vaccine Sales Market Forecast, 2022-2032
12.11.1 Italy Vaccine Sales Industry Analysis
12.11.2 Italy Vaccine Sales Market Revenue, 2022-2032
12.11.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Italy Vaccine Sales Market Forecast, 2022-2032
12.12 Spain Vaccine Sales Market Forecast, 2022-2032
12.12.1 Spain Vaccine Sales Market Revenue, 2022-2032
12.12.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Spain Vaccine Sales Market Forecast, 2022-2032
12.13 Russia Vaccine Sales Market Forecast, 2022-2032
12.13.1 Impact on Sputnik V Due to Russia Invasion of Ukraine
12.13.2 Russia Vaccine Sales Market Revenue, 2022-2032
12.13.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Russia Vaccine Sales Market Forecast, 2022-2032
12.14 Rest of Europe Vaccine Sales Market Forecast, 2022-2032
12.14.1 Rest of Europe Vaccine Sales Market Revenue, 2022-2032
12.14.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Europe Vaccine Sales Market Forecast, 2022-2032
13 Asia Pacific Vaccine Sales Market
13.1 Introduction
13.2 Asia Pacific Vaccine Sales Market by Country, Forecast 2022-2032
13.3 Asia Pacific Vaccine Sales Market Forecast by Indication
13.4 Asia Pacific Vaccine Sales Market Forecast by Route of Administration
13.5 Asia Pacific Vaccine Sales Market Forecast by Type
13.6 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel
13.7 Asia Pacific Vaccine Sales Market Forecast by Age Group
13.8 Japan Vaccine Sales Market Forecast, 2022-2032
13.8.1 Japan Vaccine Sales Industry Analysis
13.8.2 Japan Vaccine Sales Market Revenue, 2022-2032
13.8.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Japan Vaccine Sales Market Forecast, 2022-2032
13.9 China Vaccine Sales Market Forecast, 2022-2032
13.9.1 China Vaccine Sales Industry Analysis
13.9.2 China Vaccine Sales Market Revenue, 2022-2032
13.9.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): China Vaccine Sales Market Forecast, 2022-2032
13.10 India Vaccine Sales Market Forecast, 2022-2032
13.10.1 India Vaccine Sales Industry Analysis
13.10.2 Indian Vaccines Industry Has a Huge Internal Market to be Serviced
13.10.3 Research and Development in India for Vaccines Innovation and Invention
13.10.4 India Vaccine Sales Market Revenue, 2022-2032
13.10.5 COVID-19 Impact Recovery Scenarios (V, U, W, L): India Vaccine Sales Market Forecast, 2022-2032
13.11 Australia Vaccine Sales Market Forecast, 2022-2032
13.11.1 Australia Vaccine Sales Industry Analysis
13.11.2 Australia Vaccine Sales Market Revenue, 2022-2032
13.11.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Australia Vaccine Sales Market Forecast, 2022-2032
13.12 Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032
13.12.1 Rest of Asia Pacific Vaccine Sales Market Revenue, 2022-2032
13.12.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032
14 Latin America Vaccine Sales Market
14.1 Introduction
14.2 Latin America Vaccine Sales Market by Country, Forecast 2022-2032
14.3 Latin America Vaccine Sales Market Forecast by Indication
14.4 Latin America Vaccine Sales Market Forecast by Route of Administration
14.5 Latin America Vaccine Sales Market Forecast by Type
14.6 Latin America Vaccine Sales Market Forecast by Distribution Channel
14.7 Latin America Vaccine Sales Market Forecast by Age Group
14.8 Brazil Vaccine Sales Market Forecast, 2022-2032
14.8.1 Brazil Vaccine Sales Industry Analysis
14.8.2 Public Market Accounts for 90% of Demand
14.8.3 PAHO Announced 2 Centers in Argentina and Brazil as Regional Hubs for Development of mRNA-based Vaccine Manufacturing
14.8.4 Brazil Vaccine Sales Market Revenue, 2022-2032
14.8.5 COVID-19 Impact Recovery Scenarios (V, U, W, L): Brazil Vaccine Sales Market Forecast, 2022-2032
14.9 Mexico Vaccine Sales Market Forecast, 2022-2032
14.9.1 Mexico Vaccine Sales Industry Analysis
14.9.2 Emerging Region Across Latin America
14.9.3 Mexico Vaccine Sales Market Revenue, 2022-2032
14.9.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): Mexico Vaccine Sales Market Forecast, 2022-2032
14.10 Rest of Latin America Vaccine Sales Market Forecast, 2022-2032
14.10.1 Rest of Latin America Vaccine Sales Market Revenue, 2022-2032
14.10.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Latin America Vaccine Sales Market Forecast, 2022-2032
15 Middle East and Africa Vaccine Sales Market
15.1 Introduction
15.2 Middle East and Africa Vaccine Sales Market by Country, Forecast 2022-2032
15.3 Middle East and Africa Vaccine Sales Market Forecast by Indication
15.4 Middle East and Africa Vaccine Sales Market Forecast by Route of Administration
15.5 Middle East and Africa Vaccine Sales Market Forecast by Type
15.6 Middle East and Africa Vaccine Sales Market Forecast by Distribution Channel
15.7 Middle East and Africa Vaccine Sales Market Forecast by Age Group
15.8 GCC Vaccine Sales Market Forecast, 2022-2032
15.8.1 GCC Vaccine Sales Industry Analysis
15.8.2 Gulf Nations Have United to Support COVAX
15.8.3 GCC Vaccine Sales Market Revenue, 2022-2032
15.8.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): GCC Vaccine Sales Market Forecast, 2022-2032
15.9 South Africa Vaccine Sales Market Forecast, 2022-2032
15.9.1 COVAX Delivering Vaccines to Africa
15.9.2 South Africa Vaccine Sales Industry Analysis
15.9.3 South Africa Vaccine Sales Market Revenue, 2022-2032
15.9.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): South Africa Vaccine Sales Market Forecast, 2022-2032
15.10 Rest of Middle East and Africa Vaccine Sales Market Forecast, 2022-2032
15.10.1 Rest of Middle East and Africa Vaccine Sales Market Revenue, 2022-2032
15.10.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Middle East and Africa Vaccine Sales Market Forecast, 2022-2032
16 Company Profiles
16.1 Bavarian Nordic
16.1.1 Company Snapshot
16.1.2 Company Overview
16.1.3 Financial Analysis
16.1.3.1 Net Revenue, 2015-2020
16.1.3.2 R&D Expenses, 2015-2020
16.1.3.3 Gross Profit, 2015-2020
16.1.4 Product Benchmarking
16.1.5 Recent Developments till December 2021
16.2 Bharat Biotech
16.2.1 Company Snapshot
16.2.2 Company Overview
16.2.3 Product Benchmarking
16.2.4 Recent Developments till December 2021
16.3 CSL Limited
16.3.1 Company Snapshot
16.3.2 Company Overview
16.3.3 Financial Analysis
16.3.3.1 Net Revenue, 2015-2020
16.3.3.2 R&D Expenses, 2015-2020
16.3.3.3 Gross Profit, 2015-2020
16.3.4 Product Benchmarking
16.3.5 Recent Developments till December 2021
16.4 Emergent BioSolutions Inc.
16.4.1 Company Snapshot
16.4.2 Company Overview
16.4.3 Financial Analysis
16.4.3.1 Net Revenue, 2015-2020
16.4.3.2 R&D Expenses, 2015-2020
16.4.3.3 Gross Profit, 2015-2020
16.4.4 Product Benchmarking
16.4.5 Recent Developments till December 2021
16.5 GlaxoSmithKline plc
16.5.1 Company Snapshot
16.5.2 Company Overview
16.5.3 Financial Analysis
16.5.3.1 Net Revenue, 2015-2020
16.5.3.2 R&D Expenses, 2015-2020
16.5.3.3 Gross Profit, 2015-2020
16.5.4 Product Benchmarking
16.5.5 Recent Developments till December 2021
16.6 Inovio Pharmaceuticals, Inc.
16.6.1 Company Snapshot
16.6.2 Company Overview
16.6.3 Financial Analysis
16.6.3.1 Net Revenue, 2015-2020
16.6.3.2 R&D Expenses, 2015-2020
16.6.3.3 Gross Profit, 2015-2020
16.6.4 Product Benchmarking
16.6.5 Recent Developments till December 2021
16.7 J&J
16.7.1 Company Snapshot
16.7.2 Company Overview
16.7.3 Financial Analysis
16.7.3.1 Net Revenue, 2015-2020
16.7.3.2 R&D Expenses, 2015-2020
16.7.3.3 Gross Profit, 2015-2020
16.7.4 Product Benchmarking
16.7.5 Recent Developments till December 2021
16.8 Merck Co., Inc.
16.8.1 Company Snapshot
16.8.2 Company Overview
16.8.3 Financial Analysis
16.8.3.1 Net Revenue, 2015-2020
16.8.3.2 R&D Expenses, 2015-2020
16.8.3.3 Gross Profit, 2015-2020
16.8.4 Product Benchmarking
16.8.5 Recent Developments till December 2021
16.9 Mitsubishi Tanabe Pharma Corporation
16.9.1 Company Snapshot
16.9.2 Company Overview
16.9.3 Product Benchmarking
16.9.4 Recent Developments till December 2021
16.10 Moderna, Inc.
16.10.1 Company Snapshot
16.10.2 Company Overview
16.10.3 Financial Analysis
16.10.3.1 Net Revenue, 2015-2020
16.10.3.2 R&D Expenses, 2015-2020
16.10.3.3 Gross Profit, 2015-2020
16.10.4 Product Benchmarking
16.10.5 Recent Developments till December 2021
16.11 Novavax
16.11.1 Company Snapshot
16.11.2 Company Overview
16.11.3 Financial Analysis
16.11.3.1 Net Revenue, 2015-2020
16.11.3.2 R&D Expenses, 2015-2020
16.11.3.3 Gross Profit, 2015-2020
16.11.4 Product Benchmarking
16.11.5 Recent Developments till December 2021
16.12 Panacea Biotec Ltd.
16.12.1 Company Snapshot
16.12.2 Company Overview
16.12.3 Product Benchmarking
16.13 Pfizer Inc.
16.13.1 Company Snapshot
16.13.2 Company Overview
16.13.3 Financial Analysis
16.13.3.1 Net Revenue, 2015-2020
16.13.3.2 R&D Expenses, 2015-2020
16.13.3.3 Gross Profit, 2015-2020
16.13.4 Product Benchmarking
16.13.5 Recent Developments till December 2021
16.14 Sanofi
16.14.1 Company Snapshot
16.14.2 Company Overview
16.14.3 Financial Analysis
16.14.3.1 Net Revenue, 2015-2020
16.14.3.2 R&D Expenses, 2015-2020
16.14.3.3 Gross Profit, 2015-2020
16.14.4 Product Benchmarking
16.14.5 Recent Developments till December 2021
16.15 Serum Institute of India Pvt. Ltd.
16.15.1 Company Snapshot
16.15.2 Company Overview
16.15.3 Product Benchmarking
16.15.4 Recent Developments till December 2021
16.16 AstraZeneca PLC
16.16.1 Company Snapshot
16.16.2 Company Overview
16.16.3 Financial Analysis
16.16.3.1 Net Revenue, 2015-2020
16.16.3.2 R&D Expenses, 2015-2020
16.16.3.3 Gross Profit, 2015-2020
16.16.4 Product Benchmarking
16.16.5 Recent Developments till December 2021
16.17 Sinopharm
16.17.1 Company Snapshot
16.17.2 Company Overview
16.17.3 Product Benchmarking
16.18 SINOVAC
16.18.1 Company Snapshot
16.18.2 Company Overview
16.18.3 Financial Analysis
16.18.3.1 Net Revenue, 2015-2020
16.18.3.2 R&D Expenses, 2015-2020
16.18.3.3 Gross Profit, 2015-2020
16.18.4 Product Benchmarking
16.18.5 Recent Developments till December 2021
16.19 Takeda Pharmaceutical Company Limited
16.19.1 Company Snapshot
16.19.2 Company Overview
16.19.3 Financial Analysis
16.19.3.1 Net Revenue, 2015-2020
16.19.3.2 R&D Expenses, 2015-2020
16.19.3.3 Gross Profit, 2015-2020
16.19.4 Product Benchmarking
16.19.5 Recent Developments till December 2021
16.20 Daiichi Sankyo Co., Ltd.
16.20.1 Company Snapshot
16.20.2 Company Overview
16.20.3 Financial Analysis
16.20.3.1 Net Revenue, 2015-2020
16.20.3.2 R&D Expenses, 2015-2020
16.20.3.3 Gross Profit, 2015-2020
16.20.4 Product Benchmarking
16.20.5 Recent Developments till December 2021
17 Conclusion and Recommendations
17.1 Concluding Remarks
17.2 Recommendations
List of Tables
Table 1 Global Vaccine Sales Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Global COVID-19 Vaccine Tracker by Company & Vaccine Type
Table 3 Vaccine Sales Market 2022 - 2032
Table 4 Vaccine Sales Market Forecast, 2022 - 2032: "V" Shaped Recovery
Table 5 Vaccine Sales Market Forecast, 2022 - 2032: "U" Shaped Recovery
Table 6 Vaccine Sales Market Forecast, 2022 - 2032: "W" Shaped Recovery
Table 7 Vaccine Sales Market Forecast, 2022 - 2032: "L" Shaped Recovery
Table 8 Global Vaccine Sales Market Forecast by Region, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 9 Global Vaccine Sales Market Forecast by Region, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 10 Global Vaccine Sales Market Forecast by Region, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 11 Global Vaccine Sales Market Forecast by Region, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 12 Global Vaccine Sales Market Forecast by Region, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 13 Vaccine Types
Table 14 Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 15 Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 16 Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 17 Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 18 Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 19 Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 20 Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 21 Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 22 Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 23 Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 24 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 25 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 26 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 27 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 28 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 29 Global Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%)
Table 30 Global Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 31 Global Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 32 Global Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 33 Global Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 34 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 35 Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 36 Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 37 Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 38 Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 39 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 40 North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 41 North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 42 North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 43 North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 44 North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 45 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 46 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 47 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 48 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 49 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 50 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 51 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 52 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 53 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 54 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 55 North America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%)
Table 56 North America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 57 North America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 58 North America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 59 North America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 60 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 61 North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 62 North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 63 North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 64 North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 65 U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 66 U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 67 U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 68 U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 69 U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 70 Canada Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 71 Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 72 Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 73 Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 74 Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 75 Europe Vaccine Sales Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 76 Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 77 Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 78 Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 79 Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 80 Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 81 Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 82 Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 83 Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 84 Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 85 Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 86 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 87 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 88 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 89 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 90 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 91 Europe Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%)
Table 92 Europe Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 93 Europe Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 94 Europe Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 95 Europe Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 96 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 97 Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 98 Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 99 Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 100 Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 101 Germany Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 102 Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 103 Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 104 Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 105 Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 106 UK Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 107 UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 108 UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 109 UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 110 UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 111 France Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 112 France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 113 France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 114 France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 115 France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 116 Italy Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 117 Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 118 Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 119 Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 120 Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 121 Spain Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 122 Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 123 Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 124 Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 125 Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 126 Russia Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 127 Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 128 Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 129 Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
